10-K: WEED Inc. Files 10-K, Outlines Cannabis Research and Development Plans Amidst Financial Challenges

WEED Inc.'s 10-K filing details its ongoing cannabis research and development efforts, including a genomic study and plans for infused beverages, while acknowledging significant financial hurdles.

Summary

• WEED Inc. is focused on cannabis and hemp research, product development, and related services, with long-term goals including cures for diseases using the Cannabaceae plant.
• The company is working on both indoor and outdoor cultivation for research, product development, and manufacturing of pharmaceutical and non-pharmaceutical products.
• WEED acquired a 43-acre property in New York with water extraction rights to enter the hemp and infused beverage markets.
• The company has established WEED Australia Ltd. and the Cannabis Institute of Australia for research and development in Australia.
• WEED's subsidiary, Sangre AT, LLC, is conducting a Cannabis Genomic Study to create a genetic blueprint of the cannabis plant, having completed a pilot study at a cost of nearly $1 million USD.
• WEED Israel Cannabis Ltd. was formed to conduct clinical trials and product development, with plans to work with Professor Elka Touitou.
• The company aims to develop new cannabis and hemp strains for medicinal and adult-use markets, focusing on improved therapeutic properties and intellectual property protection.
• WEED is seeking to achieve a 38%-40% THC plant for controlled dosing and is also conducting studies on CBD.
• The company has not generated any revenue since its inception and is dependent on raising additional capital to execute its business plans.
• WEED has experienced negative cash flows and expects these to continue for the foreseeable future, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive aspects such as the company's research efforts and strategic acquisitions, the significant financial challenges and going concern issues weigh heavily on the overall sentiment. The company's dependence on future capital raises and the risks associated with the cannabis industry contribute to a negative outlook.

Positives

• The company has a clear focus on research and development in the cannabis and hemp industry.
• WEED has acquired a property with significant water rights, which could be valuable for future operations.
• The company has completed a pilot study for its Cannabis Genomic Study, laying the groundwork for future research.
• WEED has established international subsidiaries in Australia and Israel, expanding its global reach.
• The company has a strong team of scientists and researchers working on its genomic study.
• WEED has reduced its operating loss and overall net loss compared to the previous year.
• The company has generated a significant gain on the sale of a property.

Negatives

• WEED has not generated any revenue since its inception.
• The company has limited cash liquidity and capital resources.
• WEED has experienced negative cash flows from operations and expects this to continue.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company needs to raise substantial additional capital to complete its research and development plans.
• WEED has material weaknesses in its internal controls over financial reporting.
• The company is dependent on laws pertaining to the cannabis industry, which are subject to change.
• The cannabis industry faces strong opposition from well-funded businesses, including the pharmaceutical industry.
• The company's common stock is thinly traded and subject to penny stock rules.

Risks

• The company has a limited operating history and may not successfully complete its studies or implement its products.
• WEED may not be able to meet its future capital needs, and any financing may be on unfavorable terms.
• The company's research and development efforts are dependent on its ability to raise additional capital.
• The cannabis industry is subject to changing laws and regulations, which could negatively impact the company's business.
• The company faces strong competition in the cannabis research market.
• WEED may be unable to adequately protect its proprietary rights.
• The company may be involved in litigation in the future.
• The company's common stock is thinly traded and may be volatile.
• The company has material weaknesses in its internal controls over financial reporting.

Future Outlook

The company plans to continue its cannabis genomic study, enter the hemp and infused beverage markets, and expand its international operations, all contingent on securing additional funding.

Management Comments

• Management believes that a diverse workforce is critical to the company's success.
• Management is committed to providing team members with the training and resources necessary to continually strengthen their skills.
• Management periodically reports to the Board regarding human capital measures and results that guide how the company attracts, retains and develops a workforce to enable its business strategies.

Industry Context

The document highlights the challenges and opportunities in the emerging cannabis industry, including the need for research, product development, and navigating complex regulations. It also notes the competition from both established and new companies in the sector.

Comparison to Industry Standards

• The document mentions several competitors in the cannabis industry, including Canopy Growth Corporation, Aurora Corporation, Cronos Group, Trulieve Cannabis Corp., TerrAscend Corporation, and Tilray Brands, Inc.
• These companies are generally larger and better financed than WEED, Inc., which is primarily a research company at this stage.
• WEED's focus on genomic research and development is a unique approach compared to companies primarily focused on cultivation and sales.
• The company's goal of achieving a 38%-40% THC plant is ambitious and would be a significant achievement if successful.
• WEED's plan to conduct clinical trials in Israel is a strategic move, given the country's advancements in cannabis research.
• The company's financial situation is significantly weaker than many of its competitors, highlighting the need for substantial capital raising.

Corporate Governance

Legal Proceedings

• The company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business.
• Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

Related Party Transactions

• The company has received loans from officers and directors, including Glenn Martin and Nicole Breen.
• The company leases its executive offices from Glenn E. Martin.
• The company has issued shares of common stock to officers and directors as compensation.
• The company acquired Hempirical Genetics, LLC from Jeffrey Miller, who then became an executive officer of WEED, Inc.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and dependence on future capital raises.
• Employees and consultants are subject to the company's ability to secure funding and continue operations.
• Customers and suppliers are not yet impacted as the company has not generated revenue.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to continue its Cannabis Genomic Study.
• WEED intends to enter the hemp and infused beverage markets.
• The company will seek to conduct clinical trials in Israel.
• WEED will look to acquire companies with revenue and unique proprietary strains.
• The company will continue to look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of its proprietary products on an international level.

Key Dates

Keywords

cannabis, hemp, genomic study, research, product development, clinical trials, infused beverages, intellectual property, capital raise, medical cannabis